Lung tumor tracking during stereotactic radiotherapy treatment with the CyberKnife: Marker placement and early results.
Lung tumor tracking during stereotactic radiotherapy with the CyberKnife requires the insertion of markers in or close to the tumor. To reduce the risk of pneumothorax, three methods of marker placement were used: 1) intravascular coil placement, 2) percutaneous intrathoracal, and 3) percutaneous extrathoracal placement. We investigated the toxicity of marker placement and the tumor response of the lung tumor tracking treatment. Markers were placed in 20 patients with 22 tumors: 13 patients received a curative treatment, seven a palliative. The median Charlson Comorbidity Score was 4 (range: 1-8). Platinum fiducials and intravascular embolisation coils were used as markers. In total, 78 markers were placed: 34 intrathoracal, 23 intravascular and 21 extrathoracal. The PTV equaled the GTV + 5 mm. A median dose of 45 Gy (range: 30-60 Gy, in 3 fractions) was prescribed to the 70-85% isodose. The response was evaluated with a CTscan performed 6-8 weeks after the last treatment and routinely thereafter. The median follow-up was 4 months (range: 2-11). No severe toxicity due to the marker placement was seen. Pneumothorax was not seen. The local control was 100%. Four tumors in four patients showed a complete response, 15 tumors in 14 patients a partial response, and three tumors in two patients with metastatic disease had stable disease. No severe toxicity of marker placement was seen due to the appropriate choice of one of the three methods. CyberKnife tumor tracking with markers is feasible and resulted in excellent tumor response. Longer follow-up is needed to validate the local control.
Nuyttens
J J
JJ
Department of Radiation Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands. j.nuyttens@erasmusmc.nl
Prévost
J-B
JB
Praag
J
J
Hoogeman
M
M
Van Klaveren
R J
RJ
Levendag
P C
PC
Pattynama
P M T
PM
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers; D002289:Carcinoma, Non-Small-Cell Lung / Q000601:surgery*; D006801:Humans; D008175:Lung Neoplasms / Q000601:surgery*; D008875:Middle Aged; D011030:Pneumothorax / Q000517:prevention & control; D016634:Radiosurgery / Q000295:instrumentation* / Q000379:methods*; D013906:Thoracoscopy / Q000379:methods
D015415:Biomarkers